Last checked at 5 Apr 2024 09:42
AstraZeneca makes "breakthrough" in treating small cell lung cancer
(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News2
AZN Share
Chat
AZN Share
Trades18,389
AZN
Live RNS1
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,118.00
Bid:
12,120.00
Ask:
12,124.00
Change:
68.00 (0.56%)
Spread:
4.00 (0.033%)
Open:
11,966.00
High:
12,162.00
Low:
11,966.00
Prev. Close:
12,050.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.AstraZeneca upbeat on latest 'Calquence' trial data
Mon, 17th Jun 2019 07:24
(Sharecast News) - AstraZeneca announced detailed results from the interim analysis of the phase 3 'ASCEND' trial on Monday, showing Calquence (acalabrutinib) significantly prolonged the time patients lived without disease progression in relapsed or refractory chronic lymphocytic leukaemia (CLL).The FTSE 100 pharmaceuticals giant said the ASCEND trial compared Calquence with the physician's choice of rituximab combined with idelalisib (IdR) or bendamustine (BR), in patients with relapsed or refractory CLL.It explained that, at a median follow-up of 16.1 months, results showed a "statistically-significant and clinically-meaningful" improvement in progression-free survival for patients treated with Calquence compared to IdR or BR, reducing the risk of disease progression or death by 69%.The median time without disease progression for patients treated with Calquence had not yet been reached, compared to 16.5 months in the control arm.At 12 months, 88% of patients on Calquence showed no disease progression compared to 68% for the control arm."These data add to the growing body of evidence to support the profile of Calquence as a selective BTK inhibitor that offers a chemotherapy-free treatment option with a favourable safety profile in chronic lymphocytic leukaemia, a life-threatening disease," said AstraZeneca's executive vice-president of oncology research and development José Baselga."These data, along with our recent positive results from the phase 3 ELEVATE-TN trial in previously-untreated chronic lymphocytic leukaemia, will serve as the foundation for regulatory submissions later this year."Paolo Ghia, professor of medical oncology at Università Vita-Salute San Raffaele in Milan, and investigator of the ASCEND trial, added that it was the first randomised trial to directly compare a BTK inhibitor as monotherapy with standard chemoimmunotherapy or idelalisib and rituximab combinations."With a significant improvement in progression-free survival and a favourable safety profile, acalabrutinib may become an important choice for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia," Dr Ghia explained.
More News
5 Apr 2024 07:50
LONDON BRIEFING: Shell to book USD600 million first-quarter write-off
(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.
Read more5 Apr 2024 07:23
AstraZeneca announces positive lung cancer treatment trial results
(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.
Read more4 Apr 2024 13:09
UK shareholder meetings calendar - next 7 days
| Friday 5 April | |
| Faron Pharmaceuticals Ltd | AGM |
| VPC Specialty Lending Investments PLC | GM re capital return via B share scheme |
| Monday 8 April | |
| Premier African Minerals Ltd | AGM |
| Tuesday 9 April | |
| Ethernity Networks Ltd | EGM re board appointments and option grants |
| Wednesday 10 April | |
| Valereum PLC | AGM |
| Wincanton PLC | GM re takeover by GXO Logistics Inc |
| Thursday 11 April | |
| AstraZeneca PLC | AGM |
| Comments and questions to newsroom@alliancenews.com | |
| A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |
3 Apr 2024 22:01
Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs
WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.
Read more3 Apr 2024 17:22
3 Apr 2024 11:02
CORRECT: AstraZeneca, Daiichi make US progress with licence approvals
(Correcting the description of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria)
Read more2 Apr 2024 15:22
London close: Stocks turn red on return from Easter break
(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.
Read more2 Apr 2024 11:50
LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth
(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.
Read more2 Apr 2024 10:25
AstraZeneca and Daiichi make US progress with latest licence approvals
(Alliance News) - AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US.
Read more2 Apr 2024 09:54
LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:
Read more2 Apr 2024 09:09
LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine
(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.
Read more2 Apr 2024 08:05
LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win
(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.
Read more2 Apr 2024 07:08
US FDA gives green light for use of AstraZeneca's Voydeva
(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).
Read more27 Mar 2024 12:02
LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data
(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.
Read more